Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Roger D. Gingrich"'
Autor:
Ghada Abusin, Margarida D. Silverman, Roger D. Gingrich, Rolla Abu-Arja, Gideon K. D. Zamba, Annette J. Schlueter
Publikováno v:
Journal of Clinical Apheresis. 28:293-300
Certain patients who receive granulocyte colony-stimulating factor (GCSF) for autologous hematopoietic stem cell (AHSC) collection fail to mobilize well enough to proceed with transplant. When plerixafor is used with GCSF, the likelihood of achieving
Autor:
Brian K. Link, Alexandra Thomas, Laura S. Jacobus, Roger D. Gingrich, Brian J. Smith, Kay M. Ristow, Matthew J. Maurer, Thomas M. Habermann, Cristine Allmer
Publikováno v:
Leukemia & Lymphoma. 51:439-446
This study evaluates the predictive value of post-therapy 18-fluoro-deoxyglucose positron emission tomography (FDG-PET), including indeterminate studies, following curative-intent therapy in diffuse large B-cell lymphoma (DLBCL). Consecutive patients
Autor:
Karen Parrott, Kevin Duff, Douglas R. Langbehn, Roger D. Gingrich, Leigh J. Beglinger, Sara Van Der Heiden
Publikováno v:
Biology of Blood and Marrow Transplantation. 12(9):928-935
Delirium has been associated with a high risk of mortality in medical patients. Despite the high incidence of delirium in patients who undergo hemapoietic stem cell transplantation (HSCT), delirium as a risk factor for death has not been examined in
Autor:
Saul Yanovich, Shelly L. Carter, Steven Z. Pavletic, Roger D. Gingrich, Nancy A. Kernan, James T. Casper, Adam Mendizabal, Esperanza B. Papadopoulos, Jean Henslee-Downey, Daniel J. Weisdorf
Publikováno v:
Blood. 106:3308-3313
Donor-derived T cells have been proposed to play a role in pathogenesis of chronic graft-versus-host disease (cGVHD). The impact of ex vivo T-cell depletion (TCD) on cGVHD was analyzed in a randomized multicenter trial involving unrelated donor marro
Publikováno v:
Annals of Hematology. 92:129-131
Autor:
Annette J. Schlueter, Raymond J. Hohl, R. G. Strauss, Masaki Hayashi, M de Magalhaes-Silverman, Roger D. Gingrich, C K Lee
Publikováno v:
Bone Marrow Transplantation. 29:647-652
Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractor
Autor:
Michael A. Andrykowski, Roger D. Gingrich, Thomas G. Burish, C. B. Greiner, Janet S. Carpenter, Elizabeth M. Altmaier, Henslee-Downey Pj, Joseph H. Antin, Matthew J. Cordova
Publikováno v:
Bone Marrow Transplantation. 20:669-679
While problems with sleep and energy level (ie fatigue) are commonly reported during recovery from bone marrow transplantation (BMT), little in-depth information regarding these two problem areas in BMT patients is available. Using both questionnaire
Autor:
Roger D. Gingrich, Carol McGarigle, Henslee-Downey Pj, Michael A. Andrykowski, Thomas G. Burish, Joseph H. Antin, Elizabeth M. Altmaier, C. B. Greiner
Publikováno v:
British Journal of Cancer
Questionnaires assessing a range of quality of life (QOL) outcomes were completed by 200 adult bone marrow transplant (BMT) recipients from five BMT treatment centres. Respondents had undergone allogeneic (46%) or autologous BMT (54%) for a haematolo
Autor:
Lucy E. DesJardin, Margarida De Magalhaes-Silverman, Roger D. Gingrich, Bradley Hiatt, Curt J. Thompson, Thomas H. Carter
Publikováno v:
Clinical Infectious Diseases. 37:e129-e131
West Nile virus (WNV) can cause severe, potentially fatal neurological illnesses, which include encephalitis, meningitis, Guillain-Barré syndrome, and anterior myelitis. Because of the short viremic phase, WNV infection is most commonly diagnosed by
Autor:
Ghada A, Abusin, Rolla F, Abu-Arja, Roger D, Gingrich, Margarida D, Silverman, Gideon K D, Zamba, Annette J, Schlueter
Publikováno v:
Journal of clinical apheresis. 28(4)
Certain patients who receive granulocyte colony-stimulating factor (GCSF) for autologous hematopoietic stem cell (AHSC) collection fail to mobilize well enough to proceed with transplant. When plerixafor is used with GCSF, the likelihood of achieving